The Evidence Architecture of a Development Program
How disease models, biomarkers, endpoints, patient context, and real-world populations determine whether evidence can support what comes next
A development program rarely fails because it generates no evidence.
More often, the evidence does not resolve the uncertainty that matters most.
A biomarker may demonstrate biological activity without establishing meaningful clinical benefit. An endpoint may move without clarifying whether the patient’s condition has materially changed. A favorable subgroup may appear without sufficient evidence that it represents a reproducible treatment response.
A study may recruit successfully while enrolling a population too narrow to explain how the intervention will perform in broader practice.
Each part of the research may be technically defensible.
The architecture connecting those parts may still be incomplete.
That distinction matters because a development program is not simply a collection of studies. It is a connected system of assumptions, measurements, populations, and decisions. The central evidence risk is therefore not always a missing study. To read the rest of the article, click the download link below.
The evidence may exist. The connections may not.
A biomarker, endpoint, population, and study design can each appear defensible on their own while remaining misaligned with the decision the program must support.
Explore how colorectal cancer, myotonic dystrophy type 1, and Alzheimer’s disease reveal the consequences of that misalignment, and what a more connected evidence architecture can change.
